LG's human growth hormone Valtropin sales approved in Europe

Published: 2006-05-18 06:59:00

Updated: 2006-05-18 06:59:00

LG Life Science announced that the company completed the European health registration for "Human Growth Hormone" under the trademark of Valtropin (daily dosage form), which was developed by the Korean own technologies, through the company strategic business partner, BioPartner Inc. on April 26.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK